FdaApplication
NDA 216403
Identifiers
- fda_app_no: NDA216403
Properties
| Property | Value |
|---|---|
| applicant_name | TRAVERE THERAPEUTICS INC |
| application_type | NDA |
| approval_date | 2023-02-17 |
Revenue by product
FILSPARI
| Period | Revenue |
|---|---|
| Q2 2026 | $141.1M |
| Q1 2026 | $105.2M |
| Q2 2025 | $71.9M |
| Q1 2025 | $55.9M |
| Q4 2024 | $49.6M |
| Q3 2024 | $35.6M |
| Q2 2024 | $27.1M |
| Q1 2024 | $19.8M |
| Q4 2023 | $14.7M |
| Q3 2023 | $8.0M |
| Q2 2023 | $3.5M |
| Q1 2023 | $3.0M |
| Q4 2022 | $0.0M |
| Q3 2022 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| FILSPARI | SPARSENTAN | 400MG | TABLET;ORAL |
| FILSPARI | SPARSENTAN | 200MG | TABLET;ORAL |
2 products